TICKERNERD
Menu
VVOSVVOSHealthcare · Medical Devices

VVOS Stock Forecast: Vivos Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.18
+1.10% on the day

The 3 Wall Street analysts covering Vivos Therapeutics, Inc. hold a median 12-month price target of $2.5 — +1258.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.7M
Ticker Nerd rank
32 / 100
Median analyst target
$2.50
Analysts covering
3
Revenue$5.2M+34.9% y/y
Operating income−$4.8M
Net income−$5.5M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
−41.6%
YTD
−90.9%
1Y
−94.9%
From 52W high
−94.9%
From 52W low
+8.9%
$0.17
$3.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VVOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Revisions
81
Accruals
79
Volatility
36
Quality
32
Growth
30
Value
14
Issuance
10
Momentum
2

Size (97): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VVOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26VVOSHigh $3.10Median $2.50Low $0.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $0.75Median $2.50High $3.10

The green dot is the last close — the median target sits +1258.7% from it.

Recent analyst actionsNewest first

Of the 15 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 June 2026Ascendiant CapitalMaintainsBuy$3.00 → $3.10
22 Apr 2026Ascendiant CapitalMaintainsBuy—
17 Apr 2026HC Wainwright & Co.MaintainsBuy—
3 Dec 2025Ascendiant CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.InitiatesBuy—
9 Sept 2025Ascendiant CapitalMaintainsBuy—
15 Apr 2025Ascendiant CapitalMaintainsBuy—
20 Nov 2024Ascendiant CapitalReiteratesBuy—
19 Nov 2024Alliance Global PartnersMaintainsBuy—
20 Aug 2024Ascendiant CapitalMaintainsBuy—
17 Jan 2023Ascendiant CapitalInitiatesBuy$2.50
13 Aug 2021Roth CapitalMaintainsBuy$11 → $10
18 May 2021Roth CapitalMaintainsBuy$12 → $11
11 Jan 2021Craig-HallumInitiatesBuy—
5 Jan 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VVOS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VVOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Vivos Therapeutics, Inc. returned −94.9% against +17.5% for the S&P 500, dividends included.

VVOS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26VVOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VVOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Vivos Therapeutics, Inc. (VVOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
0.2×

Cheaper than 94% of US stocks

Price / book
−0.8×

Cheaper than 94% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
34.9%

Higher than 80% of US stocks

Earnings growth (YoY)
34.9%

Higher than 68% of US stocks

Gross margin
57.3%

Higher than 70% of US stocks

Operating margin
−93.6%

Higher than 14% of US stocks

Net margin
−121.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−8585.3%

Higher than 1% of US stocks

Return on assets
−56.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vivos Therapeutics, Inc. (VVOS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vivos Therapeutics, Inc. has a market value of $3.7M and an enterprise value of $15.4M.

  • Revenue in the twelve months to 30 June 2026: $20.9M. The latest quarter grew 34.9% year on year.

  • Net income over the same four quarters: −$25.6M, a −122.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.0M.

  • Shares outstanding: 13.5M.

  • Trailing P/E: −0.1×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Vivos Therapeutics, Inc. employs 268 people — $78K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

VVOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VVOSVivos Therapeutics, Inc.$3.7M
32
NXLNexalin Technology, Inc.$4.0M
25
BJDXBluejay Diagnostics, Inc.$4.0M
20
VTAKCatheter Precision, Inc.$3.3M
26
FEEDENvue Medical, Inc.$3.3M
23
XAIRBeyond Air, Inc.$3.1M
37
NUWENuwellis, Inc.$2.8M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VVOS news & analysis

Vivos Therapeutics Announces Material Debt Reduction

GlobeNewsWire · 8 Sept 2026positive

Vivos Therapeutics announced that on August 31, 2026, it entered into twelve exchange agreements with Streeterville Capital, LLC, converting $2,861,270 of outstanding principal under its secured promissory note into 11,445,080 shares of common stock at an exchange price of $0.25 per share.

Why it matters — This transaction reduces Vivos's outstanding debt under its secured promissory note, which could improve the company's balance sheet and financial flexibility.

Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference

Newsfile Corp · 1 Sept 2026neutral

Vivos Therapeutics announced that its Founder and CEO R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference, scheduled for September 9-10, 2026, in New York City.

Why it matters — VVOS watchers would care because the company's CEO presenting at a life sciences conference could raise visibility and interest in Vivos among investors and industry participants.

Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

GlobeNewsWire · 28 Aug 2026positive

Vivos Therapeutics announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates to support the establishment and operation of a regional Sleep & Airway Medicine Center in Palm Beach County, Florida. The center is intended to support diagnosis and treatment for obstructive sleep apnea and related conditions.

Why it matters — VVOS watchers would care because this expands the company's commercial footprint into a new regional sleep testing and treatment center, strengthening its healthcare services delivery model.

FAQ

Frequently asked questions about VVOS stock

What is the VVOS stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Vivos Therapeutics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VVOS stock a buy right now?

Of the 3 analysts covering Vivos Therapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VVOS?

As at 12 Sept 2026, Vivos Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will VVOS stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1258.7% from the last close, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 32 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VVOS stock forecast for 2030?

No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.

How has VVOS stock performed over the past year?

Vivos Therapeutics, Inc. returned -94.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vivos Therapeutics, Inc. do?

Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions.

What is the latest news on VVOS?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Vivos Therapeutics Announces Material Debt Reduction". Vivos Therapeutics announced that on August 31, 2026, it entered into twelve exchange agreements with Streeterville Capital, LLC, converting $2,861,270 of outstanding principal under its secured promissory note into 11,445,080 shares of common stock at an exchange price of $0.25 per share.

Company

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness. Its current offerings also include the VivoScore Program, which provides screening and home sleep testing for adults and children, along with related appliances, treatment protocols, and support services. Vivos Therapeutics works primarily with licensed professionals, especially general dentists, in the United States and Canada, positioning its products within the broader sleep-disordered breathing and oral appliance therapy markets. Based in Littleton, Colorado, the company serves as a specialized provider in the healthcare technology sector.

CEO Mr. R. Kirk Huntsman · 268 employees · United States · https://www.vivos.com